Home > Publications Database > Alpha-Synuclein Pathology in Down Syndrome-Associated Alzheimer's Disease: Insights from Seed Amplification Assay and Neuropathology > print

001     283150
005     20260128104031.0
024 7 _ |a 10.1002/alz70856_106390
|2 doi
024 7 _ |a pmid:41500202
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2026-00046
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rodríguez-Baz, Íñigo
|b 0
111 2 _ |a Alzheimer’s Association International Conference
|g AAIC 25
|c Toronto
|d 2025-07-27 - 2025-07-31
|w Canada
245 _ _ |a Alpha-Synuclein Pathology in Down Syndrome-Associated Alzheimer's Disease: Insights from Seed Amplification Assay and Neuropathology
260 _ _ |c 2025
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1769591358_29846
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Down syndrome (DS) is a genetic cause of Alzheimer's disease (AD), with virtually all individuals developing AD pathology by their fourth decade due to Amyloid Precursor Protein (APP) gene overexpression. In addition to amyloid beta (Aβ) plaques and hyperphosphorylated tau (p-Tau) aggregates, DS-associated AD (DSAD) often includes α-synuclein (αSyn) aggregates, contributing to Lewy body pathology (LBP). The αSyn Seed Amplification Assay (SAA) in cerebrospinal fluid (CSF) enables the in vivo detection of misfolded αSyn. While αSyn-SAA has revealed αSyn pathology in autosomal dominant (6%-11%) and sporadic (21%-45%) AD, its role in DSAD remains unexplored. This study investigates αSyn-SAA positivity in DSAD, linking in vivo findings to fluid biomarkers and neuropathology.We analyzed CSF of 270 adults with DS from the DABNI and AD21 cohorts by αSyn-SAA, encompassing asymptomatic and symptomatic AD stages (prodromal/dementia). Additional biomarkers included CSF Aβ1-42/1-40, CSF and plasma p-Tau181 and neurofilament light chain (NfL) levels. Neuropathological evaluations in 19 brain donors, including 5 with antemortem CSF, assessed AD neuropathology and LBP.As shown in Table 1, αSyn-SAA positivity was observed in 9.2% of participants, consistent across age groups (Figure 1) and cognitive stages. Symptomatic αSyn-SAA-positive individuals exhibited significantly higher plasma NfL levels compared to αSyn-SAA-negative individuals (31.0 vs. 21.1 pg/mL, p = 0.027). Neuropathological analysis revealed LBP in 47% of cases, with the amygdala and olfactory bulb being the most frequently affected regions (Table 2). Among the five donors with antemortem CSF, the only αSyn-SAA-positive case corresponded to an individual with severe neocortical LBP.This study examines the relationship between LBP and DSAD, identifying a prevalence of αSyn-SAA positivity comparable to autosomal dominant AD but lower than sporadic AD. A potential association was noted between severe neocortical LBP and αSyn seeding activity, while age and cognitive status did not significantly influence positivity rates. Misfolded αSyn was detectable from early ages in individuals with DS. Further research is required to elucidate the mechanisms underlying LBP in DSAD, assess its clinical impact on cognitive and motor symptoms, and explore relationships with other biomarkers.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: pathology
|2 MeSH
650 _ 2 |a alpha-Synuclein: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Down Syndrome: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Down Syndrome: pathology
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Peptide Fragments: cerebrospinal fluid
|2 MeSH
700 1 _ |a Bernhardt, Alexander M
|0 P:(DE-2719)9002620
|b 1
|u dzne
700 1 _ |a Aldecoa, Iban
|b 2
700 1 _ |a Arranz, Javier
|b 3
700 1 _ |a Arriola-Infante, José Enrique
|b 4
700 1 _ |a Maure-Blesa, Lucía
|b 5
700 1 _ |a Carmona-Iragui, Maria
|b 6
700 1 _ |a Longen, Sebastian
|b 7
700 1 _ |a Trossbach, Svenja Verena
|b 8
700 1 _ |a Giese, Armin
|b 9
700 1 _ |a Matthias, Torsten
|b 10
700 1 _ |a Benejam, Bessy
|b 11
700 1 _ |a Videla, Laura
|b 12
700 1 _ |a Hoyo, Laura Del
|b 13
700 1 _ |a Barroeta, Isabel
|b 14
700 1 _ |a Hernandez, Aida Sanjuan
|b 15
700 1 _ |a Fernandez, Susana
|b 16
700 1 _ |a Vaqué-Alcázar, Lídia
|b 17
700 1 _ |a Aranha, Mateus Rozalem
|b 18
700 1 _ |a Morcillo-Nieto, Alejandra O
|b 19
700 1 _ |a Nübling, Georg
|0 P:(DE-2719)9001761
|b 20
|u dzne
700 1 _ |a Wagemann, Olivia
|0 P:(DE-2719)9001249
|b 21
|u dzne
700 1 _ |a Stockbauer, Anna
|0 P:(DE-2719)9002610
|b 22
|u dzne
700 1 _ |a Tondo, Mireia
|b 23
700 1 _ |a Bejanin, Alexandre
|b 24
700 1 _ |a Lleó, Alberto
|b 25
700 1 _ |a Alcolea, Daniel
|b 26
700 1 _ |a Molina, Laura
|b 27
700 1 _ |a Fortea, Juan
|b 28
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 29
|e Last author
|u dzne
773 _ _ |a 10.1002/alz70856_106390
|g Vol. 21 Suppl 2, no. S2, p. e106390
|0 PERI:(DE-600)2201940-6
|n S2
|p e106390
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283150/files/DZNE-2026-00046.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283150/files/DZNE-2026-00046.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:283150
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002620
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)9001761
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)9001249
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)9002610
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2811659
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 1
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 2
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1110008
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21